HanAll Biopharma Reports Third Quarter 2022 Results and Prov

Financial results for Q3 2022 ended with revenue of KRW 29.6 billion with continued growth in the pharmaceutical division driven by product portfo...

Related Keywords

China , Seoul , Soult Ukpyolsi , South Korea , Japan , Chicago , Illinois , United States , Sean Jeong , Joseph Tauber , Hanall Biopharma , Co Ltd , Pipeline Development , World Cornea Congress , Daewoong Pharmaceutical Co , Devices Agency , Data Monitoring Committee , Hanall Biopharma Co Ltd , Development Highlights , Project Code , All Biopharma , Medical Devices Agency , Daewoong Pharmaceutical , Independent Data Monitoring Committee , Harbour Biomed ,